1. The T- and B-cell Malignancy Study Group, Statistical Analyses of Clinico-Pathological, Virological and Epidemiological Data on Lymphoid Malignancies with Special Reference to Adult T-Cell Leukemia/Lymphoma: A Report of the Second Nationwide Study of Japan. Jpn J Clin Oncol 1985; 15: 517-35.
2. Kadin ME, Berard CW, Nanba K et al. Lymphoproliferative diseases in Japan and western countries. Human Pathology 1983; 14: 745–7.
3. Shimoyama M, Ota K, Kikuchi M et al. For the Lymphoma study group (1981–1983), Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin’s lymphoma treated with VEPA or VEPA-M. J Clin Oncol 1988; 6: 128–41.
4. Shimoyama M, Ota K, Kikuchi M et al. For the Lymphoma Study Group (1981–1983), Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia. J Clin Oncol 1988; 6: 1088–97.
5. Shimoyama M, Ota K, Kikuchi M et al. For The Lymphoma Study Group (1981–1983), Major prognostic factors of adult patients with advanced B-cell lymphoma treated with vincristine, cyclophosphamide, prednisone and doxorubicin (VEPA) or VEPA plus methotrexate (VEPA-M). Jpn J Clin Oncol 1988; 18: 113–24.